Compare PMTS & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | MGTX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.4M | 909.1M |
| IPO Year | 2015 | 2018 |
| Metric | PMTS | MGTX |
|---|---|---|
| Price | $16.08 | $9.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $27.67 | $24.57 |
| AVG Volume (30 Days) | 39.2K | ★ 686.8K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $312,189,000.00 | $81,391,000.00 |
| Revenue This Year | $9.95 | $141.38 |
| Revenue Next Year | $10.02 | N/A |
| P/E Ratio | $92.29 | ★ N/A |
| Revenue Growth | 12.27 | ★ 144.57 |
| 52 Week Low | $10.81 | $5.02 |
| 52 Week High | $25.37 | $11.85 |
| Indicator | PMTS | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 51.51 |
| Support Level | $13.87 | $7.13 |
| Resistance Level | $16.38 | $9.65 |
| Average True Range (ATR) | 1.16 | 0.48 |
| MACD | -0.10 | -0.08 |
| Stochastic Oscillator | 31.92 | 49.22 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.